Literature DB >> 30670445

Genetic predisposition to MDS: clinical features and clonal evolution.

Alyssa L Kennedy1, Akiko Shimamura1.   

Abstract

Myelodysplastic syndrome (MDS) typically presents in older adults with the acquisition of age-related somatic mutations, whereas MDS presenting in children and younger adults is more frequently associated with germline genetic predisposition. Germline predisposition is increasingly recognized in MDS presenting at older ages as well. Although each individual genetic disorder is rare, as a group, the genetic MDS disorders account for a significant subset of MDS in children and young adults. Because many patients lack overt syndromic features, genetic testing plays an important role in the diagnostic evaluation. This review provides an overview of syndromes associated with genetic predisposition to MDS, discusses implications for clinical evaluation and management, and explores scientific insights gleaned from the study of MDS predisposition syndromes. The effects of germline genetic context on the selective pressures driving somatic clonal evolution are explored. Elucidation of the molecular and genetic pathways driving clonal evolution may inform surveillance and risk stratification, and may lead to the development of novel therapeutic strategies.
© 2019 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30670445      PMCID: PMC6405331          DOI: 10.1182/blood-2018-10-844662

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  150 in total

1.  Stable long-term risk of leukaemia in patients with severe congenital neutropenia maintained on G-CSF therapy.

Authors:  Philip S Rosenberg; Cornelia Zeidler; Audrey A Bolyard; Blanche P Alter; Mary A Bonilla; Laurence A Boxer; Yigal Dror; Sally Kinsey; Daniel C Link; Peter E Newburger; Akiko Shimamura; Karl Welte; David C Dale
Journal:  Br J Haematol       Date:  2010-04-29       Impact factor: 6.998

2.  Biallelic mutations in DNAJC21 cause Shwachman-Diamond syndrome.

Authors:  Santhosh Dhanraj; Anna Matveev; Hongbing Li; Supanun Lauhasurayotin; Lawrence Jardine; Michaela Cada; Bozana Zlateska; Chetankumar S Tailor; Joseph Zhou; Roberto Mendoza-Londono; Ajoy Vincent; Peter R Durie; Stephen W Scherer; Johanna M Rommens; Elise Heon; Yigal Dror
Journal:  Blood       Date:  2017-01-06       Impact factor: 22.113

3.  Sequential gain of mutations in severe congenital neutropenia progressing to acute myeloid leukemia.

Authors:  Renée Beekman; Marijke G Valkhof; Mathijs A Sanders; Paulette M H van Strien; Jurgen R Haanstra; Lianne Broeders; Wendy M Geertsma-Kleinekoort; Anjo J P Veerman; Peter J M Valk; Roel G Verhaak; Bob Löwenberg; Ivo P Touw
Journal:  Blood       Date:  2012-02-27       Impact factor: 22.113

4.  Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort.

Authors:  Phuong L Mai; Ana F Best; June A Peters; Rosamma M DeCastro; Payal P Khincha; Jennifer T Loud; Renée C Bremer; Philip S Rosenberg; Sharon A Savage
Journal:  Cancer       Date:  2016-08-06       Impact factor: 6.860

5.  GATA2 deficiency-associated bone marrow disorder differs from idiopathic aplastic anemia.

Authors:  Karthik A Ganapathi; Danielle M Townsley; Amy P Hsu; Diane C Arthur; Christa S Zerbe; Jennifer Cuellar-Rodriguez; Dennis D Hickstein; Sergio D Rosenzweig; Raul C Braylan; Neal S Young; Steven M Holland; Katherine R Calvo
Journal:  Blood       Date:  2014-10-30       Impact factor: 22.113

6.  Classification of and risk factors for hematologic complications in a French national cohort of 102 patients with Shwachman-Diamond syndrome.

Authors:  Jean Donadieu; Odile Fenneteau; Blandine Beaupain; Sandrine Beaufils; Florence Bellanger; Nizar Mahlaoui; Anne Lambilliotte; Nathalie Aladjidi; Yves Bertrand; Valérie Mialou; Christine Perot; Gérard Michel; Fanny Fouyssac; Catherine Paillard; Virginie Gandemer; Patrick Boutard; Jacques Schmitz; Alain Morali; Thierry Leblanc; Christine Bellanné-Chantelot
Journal:  Haematologica       Date:  2012-04-04       Impact factor: 9.941

Review 7.  The Fanconi anaemia pathway: new players and new functions.

Authors:  Raphael Ceccaldi; Prabha Sarangi; Alan D D'Andrea
Journal:  Nat Rev Mol Cell Biol       Date:  2016-05-05       Impact factor: 94.444

8.  Mitotic spindle destabilization and genomic instability in Shwachman-Diamond syndrome.

Authors:  Karyn M Austin; Mohan L Gupta; Scott A Coats; Asmin Tulpule; Gustavo Mostoslavsky; Alejandro B Balazs; Richard C Mulligan; George Daley; David Pellman; Akiko Shimamura
Journal:  J Clin Invest       Date:  2008-04       Impact factor: 14.808

9.  Altered translation of GATA1 in Diamond-Blackfan anemia.

Authors:  Leif S Ludwig; Hanna T Gazda; Jennifer C Eng; Stephen W Eichhorn; Prathapan Thiru; Roxanne Ghazvinian; Tracy I George; Jason R Gotlib; Alan H Beggs; Colin A Sieff; Harvey F Lodish; Eric S Lander; Vijay G Sankaran
Journal:  Nat Med       Date:  2014-06-22       Impact factor: 53.440

10.  Germline heterozygous DDX41 variants in a subset of familial myelodysplasia and acute myeloid leukemia.

Authors:  S R Cardoso; G Ryan; A J Walne; A Ellison; R Lowe; H Tummala; A Rio-Machin; L Collopy; A Al Seraihi; Y Wallis; P Page; S Akiki; J Fitzgibbon; T Vulliamy; I Dokal
Journal:  Leukemia       Date:  2016-06-02       Impact factor: 11.528

View more
  32 in total

Review 1.  Cancer and myeloid clonal evolution in the short telomere syndromes.

Authors:  Kristen E Schratz; Mary Armanios
Journal:  Curr Opin Genet Dev       Date:  2020-04-07       Impact factor: 5.578

Review 2.  Assessing clonal haematopoiesis: clinical burdens and benefits of diagnosing myelodysplastic syndrome precursor states.

Authors:  Lukasz P Gondek; Amy E DeZern
Journal:  Lancet Haematol       Date:  2019-12-03       Impact factor: 18.959

Review 3.  Unraveling Hematopoiesis through the Lens of Genomics.

Authors:  L Alexander Liggett; Vijay G Sankaran
Journal:  Cell       Date:  2020-09-17       Impact factor: 41.582

4.  Genetic predisposition to MDS: diagnosis and management.

Authors:  Elissa Furutani; Akiko Shimamura
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

Review 5.  Treatment of immune-mediated cytopenias in patients with primary immunodeficiencies and immune regulatory disorders (PIRDs).

Authors:  Markus G Seidel
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

Review 6.  Evidence-Based Minireview: Molecular precision and clinical uncertainty: should molecular profiling be routinely used to guide risk stratification in MDS?

Authors:  Daniel R Richardson; Amy E DeZern
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

Review 7.  Genetic Predisposition to Myelodysplastic Syndrome in Clinical Practice.

Authors:  Kristen E Schratz; Amy E DeZern
Journal:  Hematol Oncol Clin North Am       Date:  2020-01-06       Impact factor: 3.722

8.  Human mutational constraint as a tool to understand biology of rare and emerging bone marrow failure syndromes.

Authors:  Joseph H Oved; Daria V Babushok; Michele P Lambert; Nicole Wolfset; M Anna Kowalska; Mortimer Poncz; Konrad J Karczewski; Timothy S Olson
Journal:  Blood Adv       Date:  2020-10-27

Review 9.  Prognostic mutation constellations in acute myeloid leukaemia and myelodysplastic syndrome.

Authors:  Ilaria Iacobucci; Charles G Mullighan
Journal:  Curr Opin Hematol       Date:  2021-03-01       Impact factor: 3.284

10.  Germline ATG2B/GSKIP-containing 14q32 duplication predisposes to early clonal hematopoiesis leading to myeloid neoplasms.

Authors:  Jean Pegliasco; Pierre Hirsch; Christophe Marzac; Françoise Isnard; Jean-Côme Meniane; Caroline Deswarte; Philippe Pellet; Céline Lemaitre; Gwendoline Leroy; Graciela Rabadan Moraes; Hélène Guermouche; Barbara Schmaltz-Panneau; Florence Pasquier; Chrystelle Colas; Patrick R Benusiglio; Odile Bera; Jean-Henri Bourhis; Eolia Brissot; Olivier Caron; Samy Chraibi; Pascale Cony-Makhoul; Christine Delaunay-Darivon; Simona Lapusan; Flore Sicre de Fontbrune; Pascal Fuseau; Albert Najman; William Vainchenker; François Delhommeau; Jean-Baptiste Micol; Isabelle Plo; Christine Bellanné-Chantelot
Journal:  Leukemia       Date:  2021-06-25       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.